Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 17/20 | 0.47 |
| ▸ | ITGB7 | P26010 | 14/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 14/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8067917 | 0.86 | NPSR1 (0.54) | KLK5CTSSCTSK | |
| SCHEMBL7223168 | 0.83 | KLK5 (0.45) | KLK5CTSSCTSK | |
| SCHEMBL7229743 | 0.80 | CTSS (0.47) | KLK5CTSSCTSK | |
| SCHEMBL7223400 | 0.79 | KLK5 (0.43) | KLK5 | |
| SCHEMBL22962198 | 0.79 | KLK5 (0.54) | KLK5CTSSCTSK | |
| SCHEMBL8063643 | 0.78 | HTRA1 (0.46) | ITGA4ITGB1KLK5CTSSCTSK | |
| SCHEMBL7972340 | 0.78 | ECE1 (0.44) | KLK5 | |
| SCHEMBL7229463 | 0.77 | HDAC1 (0.47) | ITGA4ITGB7ITGB1KLK5CTSS | |
| SCHEMBL8304409 | 0.76 | CTSS (0.55) | KLK5CTSSCTSKPTPN1 | |
| SCHEMBL7229912 | 0.76 | HDAC1 (0.47) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613782-B2 | For treating and/or preventing endothelin dependent conditions, e.g. cardio- and cerebro-vascular disorders such as hypertension, vasoconstriction, congestive heart failure, cerebral disorders, respiratory system disorders | NOVARTIS AG (CH) | 2003-09-02 | — | — | US | disclosed |
| US-6423727-B1 | Certain thiol inhibitors of endothelin-converting enzyme | NOVARTIS AG (CH) | 2002-07-23 | — | — | US | disclosed |
| US-20020082218-A1 | Certain thiol inhibitors of endothelin-converting enzyme | LOMBAERT STEPHANE DE (US) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082218-A1 | Certain thiol inhibitors of endothelin-converting enzyme | ECE1, ECE2, EDNRB | ITGA4 2567/4885ITGB7 3410/4885ITGB1 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.